Literature DB >> 17877479

Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma.

Hidenori Toyoda1, Takashi Kumada, Yukio Osaki, Hiroko Oka, Masatoshi Kudo.   

Abstract

The efficacies of tumor markers, alfa-fetoprotein (AFP), Lens culinaris agglutinin A-reactive fraction of alfa-fetoprotein (AFP-L3), and des-gamma-carboxy prothrombin (DCP) were evaluated for assessment of progression of hepatocellular carcinoma (HCC) and patient prognosis. The prevalence of elevated levels of each tumor marker increased with progression of tumor stage for all three markers among patients with HCC. Survival was poorer among patients with elevated levels of tumor markers than among those without elevated levels.Evaluation of tumor progression with tumor markers was based only on the results of laboratory tests. The tests are objective, simple to perform, and easy to repeat, and therefore, may be useful to supplement conventional tumor staging for the evaluation of tumor progression and prediction of patient outcome.

Entities:  

Year:  2007        PMID: 17877479     DOI: 10.1111/j.1872-034X.2007.00181.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

Review 1.  Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Yuji Kaneoka; Atsuyuki Maeda
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

2.  Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey.

Authors:  Hienori Toyoda; Toshifumi Tada; Philip J Johnson; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Norihiro Kokudo; Yonson Ku; Shoji Kubo; Takashi Kumada; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2017-02-21       Impact factor: 7.527

3.  Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.

Authors:  Brian I Carr; Petr Pancoska; Robert A Branch
Journal:  Hepatol Int       Date:  2009-12-24       Impact factor: 6.047

4.  Differences in the impact of prognostic factors for hepatocellular carcinoma over time.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Tsuyoki Yama; Kazuyuki Mizuno; Yasuhiro Sone; Atsuyuki Maeda; Yuji Kaneoka; Tomoyuki Akita; Junko Tanaka
Journal:  Cancer Sci       Date:  2017-10-20       Impact factor: 6.716

5.  Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response.

Authors:  Yasunori Minami; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2022-10-04       Impact factor: 6.575

6.  Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model.

Authors:  R Fox; S Berhane; M Teng; T Cox; T Tada; H Toyoda; T Kumada; C Kagebayashi; S Satomura; P J Johnson
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640

7.  Prognostic Role of Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Level in Early Stage Hepatocellular Carcinoma.

Authors:  Joseph Lin; Chih-Jan Ko; Yu-Ju Hung; Ping-Yi Lin; Kuo-Hua Lin; Chia-En Hsieh; Chen-Te Chou; Yao-Li Chen
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.